Home Newsfeeds BMO Capital Maintains Outperform on Visa, Lowers Price Target to $241

BMO Capital Maintains Outperform on Visa, Lowers Price Target to $241

BMO Capital analyst James Fotheringham maintains Visa (NYSE:V) with a Outperform and lowers the price target from $257 to $241.

byBenzinga Newsdesk

October 27, 2022

1 minute read

BMO Capital analyst James Fotheringham maintains Visa (NYSE:V) with a Outperform and lowers the price target from $257 to $241.

Ethereum Whales Sold 1.5 Trillion Shiba Inu (SHIB) Tokens In 2 Days

By Samyuktha Sriram

August 23, 11:38 PM

On-chain data shows that the richest Ethereum (CRYPTO: ETH) whales have been selling a large amount of Shiba Inu (CRYPTO: SHIB) tokens over the last two days.

$DOGE

Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target

By Benzinga Newsdesk

March 8, 8:56 AM

Cantor Fitzgerald analyst Charles Duncan reiterates Marinus Pharma (NASDAQ:MRNS) with a Overweight and maintains $28 price target.

MRNS

Morgan Stanley Downgrades Aptiv to Equal-Weight, Lowers Price Target to $105

By Benzinga Newsdesk

November 28, 7:40 AM

Morgan Stanley analyst Adam Jonas downgrades Aptiv (NYSE:APTV) from Overweight to Equal-Weight and lowers the price target from $120 to $105.

APTV

Body and Mind Reports Revenue Dip In 2023 But CEO Is Optimistic About Future Growth

By Jelena Martinovic

November 14, 12:03 PM

Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) announced its financial results on Tuesday for the fiscal year ended July 31, 2023, revealing a 2.4% year-over-year decrease to $22.8 million.

BMMJ

BMO Capital Maintains Outperform on Visa, Lowers Price Target to $241

Related Posts

Ethereum Whales Sold 1.5 Trillion Shiba Inu (SHIB) Tokens In 2 Days

Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target

Morgan Stanley Downgrades Aptiv to Equal-Weight, Lowers Price Target to $105

Body and Mind Reports Revenue Dip In 2023 But CEO Is Optimistic About Future Growth